What Do Medical Professionals Say About Cannabis for AS? 

As interest in cannabis for Ankylosing Spondylitis (AS) grows, patients often ask: what’s the current medical opinion? With insufficient evidence for mainstream adoption, reviewing expert perspectives and clinical positions is essential for informed decisions about cannabis in AS use. 

How Cannabis Is Being Viewed in Rheumatology and Pain Medicine 

Across specialities, expert cannabis review reveals a range of views: 

• Some rheumatologists remain cautious, citing limited robust trials and a lack of AS‑specific evidence. 

• Pain medicine specialists may be more open, particularly when using cannabis as part of a multimodal strategy. 

• GPs and general practitioners often face queries from patients and may support cautious trials under supervision. 

Overall, cannabis in AS is acknowledged for symptom management, but professionals emphasise the need for high-quality clinical data before endorsing use. 

What Do Doctors Say About Cannabis Use for AS? 

Opinions vary by field: 

• GPs: Typically support a measured, patient-centred approach. They may oversee low-dose trials if conventional options have been exhausted. This reflects a pragmatic medical opinion that values symptom relief but stresses professional oversight. 

• Rheumatologists: Often hold a more conservative stance, reinforcing first-line use of NSAIDs, biologics, and physiotherapy. While some recognise potential ancillary benefits of cannabis, they emphasise the absence of evidence on slowing structural degeneration. 

• Pain specialists: In some settings, cannabis is already included in chronic pain management protocols. Here, doctor views on cannabis tend to favour symptom-level benefits, with caution around dosing and source consistency. 

What Medical Guidelines Say About AS and Cannabis 

In the UK, regulatory bodies like NICE do not formally endorse cannabis for AS. Their AS treatment advice focuses on pain relief but stops short of recommending cannabis in treatment pathways. Key points include: 

• Cannabis is not listed among approved AS therapies due to limited clinical evidence. 

• NICE emphasises symptom-only use and urges consideration of mental health risks. 

• Without clear evidence of disease modification, most guidelines classify cannabis as a third-line or adjunct treatment. 

As a result, cannabis in AS remains outside standard care, acknowledged experimentally but not officially recommended. 

Key Concerns Raised by Professionals 

During expert cannabis review, clinicians frequently highlight: 

• Dosing inconsistency: Variability in cannabinoid content between products makes prescribing challenging. 

• Lack of long-term safety data: This raises concerns about potential side effects and dependency with chronic use. 

• Psychological and cognitive effects: THC-heavy products may carry risks for anxiety or mood disturbance, especially in younger or vulnerable populations. 

These caveats reflect a cautious medical opinion, underscoring the need for careful risk-benefit assessment and specialist guidance. 

Final Thoughts 

The medical opinion on cannabis for Ankylosing Spondylitis remains guarded. While cannabis AS can offer meaningful doctor views on cannabis from a symptom-control perspective, mainstream medicine awaits robust data, especially regarding safety, dosing, and long-term effects. 

If you’re exploring cannabis, always: 

• Consult your GP or rheumatologist. 

• Treat cannabis as an adjunct, not a replacement, for standard therapies. 

• Discuss product selection, dosing, and timing meticulously. 

• Stay informed about emerging studies and clinical trials. 

Book a consultation with a healthcare professional via LeafEase. 

For now, cannabis in AS remains an area of cautious exploration that is supported by real-world use in some practices yet not yet embraced in formal treatment guidelines. Medical professionals consistently recommend a balanced, informed approach that prioritises existing evidence and patient safety.